Immune Design Corp (IMDZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Immune Design Corp (IMDZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH139803D
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Immune Design's product candidates are used for the treatment of NY-ESO-1 tumor antigen, merkel cell carcinoma, non-hodgkin lymphoma, and others. It has collaboration with various pharmaceutical companies, to develop its product candidates through its GLAAS platform for the treatment of infectious disease, allergy and autoimmune diseases. Immune Design is headquartered in Seattle, Washington, the US.

Immune Design Corp (IMDZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Immune Design Corp, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Immune Design Raises USD 32.5 Million In Series C Financing 12

Immune Design Raises USD 34 Million In Series B Financing 14

Partnerships 15

Immune Design Enters into Agreement with Gritstone Oncology 15

Immune Design Enters into Clinical Trial Collaboration with Genentech 16

Immune Design Enters into Clinical Collaboration Agreement with Merck 17

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 18

Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 19

Licensing Agreements 21

Sanofi Enters into Licensing Agreement with Immune Design 21

Immune Design Enters into Licensing Agreement with UNC Chapel Hill 22

Immune Design Licensing Agreement with Oxford BioMedica 23

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 24

Equity Offering 25

Immune Design Prices USD80 Million in Public Offering of Shares 25

Immune Design Prices Public Offering of Shares for USD30 Million 27

Immune design Plans to Raise up to USD50 Million in Public offering of Shares 29

Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 30

Immune Design Raises USD60 Million in IPO 32

Immune Design Corp-Key Competitors 34

Immune Design Corp-Key Employees 35

Immune Design Corp-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 01, 2018: Immune Design reports second quarter 2018 financial results and provides corporate update 37

Mar 14, 2018: Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 39

Nov 01, 2017: Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update 41

Aug 02, 2017: Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update 43

May 17, 2017: Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update 45

Mar 07, 2017: Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 47

Product News 49

09/25/2017: Immune Design Announces Upcoming Presentations at the SITC 32nd Annual Meeting 49

06/05/2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 50

06/01/2017: Immune responses from early study of novel sarcoma vaccine 52

05/17/2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program 54

Clinical Trials 56

May 24, 2018: Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma 56

Mar 12, 2018: Immune Design Reports Data Update for Lead Immunotherapy Program: Improvement in Survival for CMB305 Monotherapy in Sarcoma 57

Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients 58

Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response 59

Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress 61

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63

List of Figures

Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Immune Design Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immune Design Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Immune Design Raises USD 32.5 Million In Series C Financing 12

Immune Design Raises USD 34 Million In Series B Financing 14

Immune Design Enters into Agreement with Gritstone Oncology 15

Immune Design Enters into Clinical Trial Collaboration with Genentech 16

Immune Design Enters into Clinical Collaboration Agreement with Merck 17

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 18

Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 19

Sanofi Enters into Licensing Agreement with Immune Design 21

Immune Design Enters into Licensing Agreement with UNC Chapel Hill 22

Immune Design Licensing Agreement with Oxford BioMedica 23

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 24

Immune Design Prices USD80 Million in Public Offering of Shares 25

Immune Design Prices Public Offering of Shares for USD30 Million 27

Immune design Plans to Raise up to USD50 Million in Public offering of Shares 29

Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 30

Immune Design Raises USD60 Million in IPO 32

Immune Design Corp, Key Competitors 34

Immune Design Corp, Key Employees 35

Immune Design Corp, Other Locations 36

Immune Design Corp, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Immune Design Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17773
Site License
USD 500 INR 35545
Corporate User License
USD 750 INR 53318

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com